# Caris Life Sciences

推出 Caris Detect，并为非小细胞肺癌患者引入 AI 驱动的分子洞察，同时推出预测乳腺癌与肺癌脑转移风险的 AI 模型、其 Caris ChromoSeq 检测，以及基于血液的 Caris Assure 检测。

Source: https://cn.bioecon.ru/companies/caris-life-sciences/
Updated: 2026-07-20

- 国家: United States
- 代码: CAI

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 产能 | 四个实验室总面积超过275,000平方英尺 | https://investor.carislifesciences.com/static-files/94e5ccde-41c7-4154-b11f-e19b56a4a5ec |
| 认证 | 2026-08-05向SEC提交Rule 13A-14(A)/15D-14(A)及Section 1350证明文件 | https://last10k.com/sec-filings/cai/0002019410-26-000055.htm |
| 监管批准 | 2024年11月MI Cancer Seek获得FDA批准 | https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-advances-precision-oncology-with-new-ai-insights-predicting-brain-metastases-risk-in-breast-and-lung-cancer/, https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-introduces-ai-powered-molecular-insights-for-nsclc-patients/ |
| 监管批准 | 截至2026-08-05，Caris ChromoSeq已获得MolDX批准 | https://www.prnewswire.com/news-releases/caris-life-sciences-reports-second-quarter-2026-financial-results-and-increases-2026-revenue-guidance-302843876.html |
| 生产基地 | 四个实验室总面积超过275,000平方英尺 | https://investor.carislifesciences.com/static-files/94e5ccde-41c7-4154-b11f-e19b56a4a5ec |
| 营收 | 截至2026年6月30日止季度为$263.7 million | https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-reports-second-quarter-2026-financial-results-and-increases-2026-revenue-guidance/ |
| 营收 | 预计2026全年为$10.3亿至$10.4亿 | https://www.prnewswire.com/news-releases/caris-life-sciences-reports-second-quarter-2026-financial-results-and-increases-2026-revenue-guidance-302843876.html |

独立来源: last10k.com, prnewswire.com

## 技术

- [精准肿瘤学多组学诊断panel](https://cn.bioecon.ru/technology/multi-omics-diagnostic-panels-precision-oncology/)